RxDoctor Payments Data

Cynthia Miller, MD

Pulmonary Disease · Long Beach, CANPI 1437245669

Payments from drug & device makers

$3,078in general payments, 2019–2025

Across 281 payments — averaging $10.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$2K
  • Neurocrine Biosciences, Inc.$123
  • AstraZeneca$69
  • Mylan Specialty L.p.$59
  • Avanir Pharmaceuticals, Inc.$54
  • UCB, Inc.$47
  • plus $305 from 11 others

What the payments were for

  • Food & beverage$3,078100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,078 in reported general payments places this provider in the 60th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$344,146
Medicare patients
156
Services billed
2,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban207$54,752
Abilify MaintenaAripiprazole18$54,061
IngrezzaValbenazine Tosylate11$45,813
Abiraterone Acetate17$44,913
SantylCollagenase Clostridium Hist.32$33,799
AptiomEslicarbazepine Acetate54$31,657
ProcritEpoetin Alfa37$30,455
ErtapenemErtapenem Sodium42$18,213
FarxigaDapagliflozin Propanediol45$14,653
Pantoprazole Sodium170$12,576
Combivent RespimatIpratropium/Albuterol Sulfate19$11,776
JardianceEmpagliflozin37$10,739
GlatopaGlatiramer Acetate17$9,133
ArexvyRsvpref3 Antigen/As01e/Pf29$8,686
NuedextaDextromethorphan Hbr/Quinidine16$8,469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$36$54,06118 claims
Neurocrine Biosciences, Inc.Ingrezza$123$45,81311 claims
Sunovion Pharmaceuticals Inc.Aptiom$2,421$31,65754 claims
Boehringer IngelheimCombivent Respimat, Jardiance$16$22,51556 claims
AstraZenecaFarxiga, Lokelma$69$19,68266 claims
GSKArexvy, Trelegy Ellipta$24$16,80141 claims
Avanir Pharmaceuticals, Inc.Nuedexta$54$8,46916 claims
Sumitomo Pharma America, Inc.Gemtesa$40$5,50825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →